Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab in first-line CLL/SLL
2017-004699-77Phase 3Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
ibrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2017-004699-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004699-77.